Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma
Swati Gupta(Civitan International), David L. Rimm(Yale University), Jodi Weidler, Pok Fai Wong(AbbVie (United States)), James W. Smithy(Memorial Sloan Kettering Cancer Center), Leena McCann, Brian Rhees(Phoenix (United States)), Wei Wei(Zhujiang Hospital), Edwin W. Lai(Eunice Kennedy Shriver National Institute of Child Health and Human Development), Harriet M. Kluger(Yale Cancer Center), Michael Bates, Yvonne G. Y. Chan
Cited by 23
Related Papers
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
|Nature Reviews Clinical Oncology|2021|1.5k
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma
|Nature|2005|1.5k
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k